Remarks: Idarubicin HCl adaptation in adult acute non-lymphocytic leukemia the induction of remission, relapse, remission induction of refractory patients
None of the products will be supplied to countries in which this could be in conflict with the existing patents. However the final responsibility lies with the Buyer.